| Dr Alexander W Szymanski, MD | |
|
1850 E Park Ave, Ste 201, State College, PA 16803-6706 | |
| (814) 234-8800 | |
| (814) 235-1133 |
| Full Name | Dr Alexander W Szymanski |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 19 Years |
| Location | 1850 E Park Ave, State College, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255544714 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD442258 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Nittany Medical Center | State college, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mount Nittany Medical Center Health Services Inc | 8426136797 | 196 |
News Archive
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
A new study published on the preprint server medRxiv* in November 2020 suggests that a significant proportion of the Australian population is likely to show vaccine hesitancy. This indicates the need for public health messaging as well as, in some cases, other policy measures.
Improving the autonomy and care of dependent people with acquired brain injury is the scientific and technological challenge of the Retogar project led by researchers from the University of Alicante Institute for Computer Engineering Research, Miguel Cazorla and José García.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
› Verified 2 days ago
| Entity Name | Mount Nittany Medical Center Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164691499 PECOS PAC ID: 8426136797 Enrollment ID: O20081021000240 |
News Archive
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
A new study published on the preprint server medRxiv* in November 2020 suggests that a significant proportion of the Australian population is likely to show vaccine hesitancy. This indicates the need for public health messaging as well as, in some cases, other policy measures.
Improving the autonomy and care of dependent people with acquired brain injury is the scientific and technological challenge of the Retogar project led by researchers from the University of Alicante Institute for Computer Engineering Research, Miguel Cazorla and José García.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alexander W Szymanski, MD 1850 E Park Ave, Ste 201, State College, PA 16803-6706 Ph: (814) 234-8800 | Dr Alexander W Szymanski, MD 1850 E Park Ave, Ste 201, State College, PA 16803-6706 Ph: (814) 234-8800 |
News Archive
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
A new study published on the preprint server medRxiv* in November 2020 suggests that a significant proportion of the Australian population is likely to show vaccine hesitancy. This indicates the need for public health messaging as well as, in some cases, other policy measures.
Improving the autonomy and care of dependent people with acquired brain injury is the scientific and technological challenge of the Retogar project led by researchers from the University of Alicante Institute for Computer Engineering Research, Miguel Cazorla and José García.
A team of researchers from Imperial College London's Division of Molecular Biosciences has received a grant of over US $4 million to support a research facility for understanding how sugars are involved in cell to cell communication.
› Verified 2 days ago
Paul Andrew Koberna, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2134 Sandy Dr Ste 16, State College, PA 16803 Phone: 814-272-5805 Fax: 814-272-0110 | |
Peter F. Pepe, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1850 E Park Ave, Suite 201, State College, PA 16803 Phone: 814-234-8800 | |
Keriann Nickola Gray, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr., State College, PA 16801 Phone: 814-231-4560 Fax: 814-231-6246 | |
Dr. Manisha N. Patel, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-231-6246 | |
Dr. Joel B Haight, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 32 Colonnade Way, State College, PA 16803 Phone: 814-272-4445 Fax: 814-272-4450 | |
Jeffrey W. Pro, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1850 E Park Ave, Suite 302, State College, PA 16803 Phone: 814-278-4680 Fax: 814-235-1523 | |
Dr. Scott A. Sulman, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Scenery Dr, State College, PA 16801 Phone: 814-231-4560 Fax: 814-235-5512 |